ozuriftamab vedotin
ozuriftamab vedotin: developed by 1 company · 2 clinical trials tracked.
ozuriftamab vedotin evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could ozuriftamab vedotin → BCAB affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| BioAtla, Inc. (BCAB) | Phase 2 |
| BioAtla, Inc. (BCAB) | Phase 2 |
Clinical Trials (2)
A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Primary endpoint: Confirmed Objective Response Rate (ORR) per RECIST v1.1
An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Primary endpoint: To efficiently identify based on objective response rate (ORR), by investigator assessment using RECIST 1.1, promising immunotherapy combinations for the treatment of high grade serous ovarian cancer for later validation in randomized trials
Frequently asked questions
Who is developing ozuriftamab vedotin?
ozuriftamab vedotin is being developed by BioAtla, Inc..
How many clinical trials involve ozuriftamab vedotin?
BioSniper tracks 2 clinical trials involving ozuriftamab vedotin.